The site is set to benefit both domestic and international patients. Credit: Gorodenkoff via Shutterstock.

Biopharmaceutical company Akeso has broken ground on a new research and development (R&D) centre in Shanghai, China.

The ceremony for the Shanghai Global R&D Center took place at the Zhangjiang headquarters park.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Akeso has planned to spend approximately 850m yuan on the new project, which encompasses an area of 14,454.90m², with a total construction area of 66,568.86m².

The new centre represents a key move in Akeso’s strategy for global innovation and contributes to the company’s ongoing and rapid development of solutions, strengthening its global competitive position in new drug development.

Akeso chair, president, and CEO Dr Yu Xia said: “The establishment of Akeso’s global R&D centre marks a significant milestone in our unwavering commitment and confidence to expedite the implementation of our global expansion strategy.

“I eagerly anticipate collaborating with industry partners to enhance the global competitiveness of Akeso’s innovative drug research and speed up commercialisation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“By doing so, we can assist Zhangjiang in Shanghai in constructing a world-class biopharmaceutical industry cluster, facilitate the internationalisation of China’s domestic innovative drugs, and ultimately benefit Chinese and global patients.”

Utilising Akeso’s drug innovation and development system, the new centre will synchronise with the group’s R&D strategy and help it actively stay ahead of the latest global research trends.

The site aims to concentrate on the latest advancements in gene therapy, cell therapy, neurological diseases, and anti-ageing solutions.